Journal of Nuclear Cardiology

, Volume 16, Issue 3, pp 478–480 | Cite as

Initial clinical experience with a selective A2A receptor agonist, regadenoson, in a patient with end-stage renal disease on hemodialysis

Nuclear Cardiology Bullet

References

  1. 1.
    Bokhari S, Ficaro EP, McCallister BD Jr. Adenosine stress protocols for myocardial perfusion imaging. J Nucl Cardiol 2007;14:415-6.PubMedCrossRefGoogle Scholar
  2. 2.
    Lexiscan prescribing information handbook, Lexiscan (regadenoson) prescribing package insert. Deerfield, IL: Astellas Pharma; 2008.Google Scholar
  3. 3.
    Cerqueira MC, Nguyen P, et al. Effects of age, gender, obesity, and diabetes on the efficacy and safety of the selective A2A agonist regadenoson versus adenosine in myocardial perfusion imaging: Integrated ADVANCE-MPI trial results. JACC Cardiovasc Imaging 2008;1:307-16.PubMedCrossRefGoogle Scholar
  4. 4.
    Gordi T, Blackburn B, Lieu H. Regadenoson pharmacokinetics and tolerability in subjects with impaired renal function. J Clin Pharmacol 2007;47:825-33.PubMedCrossRefGoogle Scholar
  5. 5.
    Adenosine prescribing information handbook, Adenosine (adenoscan) prescribing package insert. Deerfield, IL: Astellas Pharma; 2005.Google Scholar

Copyright information

© American Society of Nuclear Cardiology 2008

Authors and Affiliations

  1. 1.Division of CardiologyNorth Shore University HospitalManhassetUSA

Personalised recommendations